血管紧张素转换酶2与动脉粥样硬化相关性的研究进展
Research Progress on Relationship between Angiotensin Converting Enzyme 2 and Atherosclerosis
DOI: 10.12677/ACM.2022.122122, PDF,   
作者: 金浩楠, 陈 鹏：昆明医科大学药学院暨云南省天然药物药理重点实验室，云南 昆明
关键词: 血管紧张素转换酶2；动脉粥样硬化；炎症反应；Angiotensin Converting Enzyme 2； Atherosclerosis； Inflammatory Response
摘要: 血管紧张素转换酶2 (ACE2)是肾素–血管紧张素系统(RAS)的负调节因子，通过抑制Ang II并催化产生Ang-(1-7)，起着保护血管、抑制炎症反应的作用。近年研究表明，在AS发生发展过程中，ACE2可以增加Ang-(1-7)的含量并增加体内超氧化物歧化酶的活性，从而保护内皮细胞免受炎症反应的影响，起到早期预防动脉粥样硬化的作用。现就ACE2对AS的治疗作用的潜在机制作一简要综述。以期为临床应用ACE2治疗AS提供参考。
Abstract: Angiotensin converting enzyme 2 (ACE2) is a negative regulator of renin-angiotensin system (RAS). By inhibiting Ang II and catalyzing it to produce Ang-(1-7), ACE2 has effect in protecting blood vessel, inhibiting inflammatory reaction. Recent studies have shown that during the occurrence and development of AS, ACE2 can increase the content of Ang-(1-7) and increase the activity of superoxide dismutase in vivo, thus protecting endothelial cells from inflammatory response and playing an early role in preventing atherosclerosis. In order to provide reference for the clinical application of ACE2, this review briefly shows the potential mechanisms of ACE2 in the treatment of AS.
文章引用：金浩楠, 陈鹏. 血管紧张素转换酶2与动脉粥样硬化相关性的研究进展[J]. 临床医学进展, 2022, 12(2): 846-851. https://doi.org/10.12677/ACM.2022.122122

参考文献

[1] Ross, R. (1999) Atherosclerosis—An Inflammatory Disease. The New England Journal of Medicine, 340, 115-126. [Google Scholar] [CrossRef] 
[2] Libby, P., Ridker, P.M. and Hansson, G.K. (2011) Progress and Challenges in Translating the Biology of Atherosclerosis. Nature, 473, 317-325. [Google Scholar] [CrossRef] [PubMed]
[3] Donoghue, M., Hsieh, F., Baronas, E., et al. (2000) A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9. Circulation Research, 87, E1-E9. [Google Scholar] [CrossRef] 
[4] Zhong, J.C., Guo, D., Chen, C.B., et al. (2011) Prevention of Angiotensin II-Mediated Renal Oxidative Stress, Inflammation and Fibrosis by Angiotensin-Converting Enzyme 2. Hypertension, 57, 314-322. [Google Scholar] [CrossRef] 
[5] Tesanovic, S., Vinh, A., Gaspari, T.A., et al. (2010) Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprote in E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 1606-1613. [Google Scholar] [CrossRef] 
[6] Thomas, M.C., Pickering, R.J., Tsorotes, D., et al. (2010) Genetic Ace2 Deficiency Accentuates Vascular Inflammation and Atherosclerosis in the ApoE Knockout Mouse. Circulation Research, 107, 888-897. [Google Scholar] [CrossRef] 
[7] Gaddam, R.R., Chambers, S. and Bhatia, M. (2014) ACE and ACE2 in Inflammation: A Tale of Two Enzymes. Inflammation & Allergy Drug Targets, 13, 224-234. [Google Scholar] [CrossRef] [PubMed]
[8] Zhu, Y.H., Xian, X.M., Wang, Z.Z., et al. (2018) Research Progress on the Relationship between Atherosclerosis and Inflammation. Biomolecules, 8, Article No. 80. [Google Scholar] [CrossRef] [PubMed]
[9] Badimon, L., Peña, E., Arderiu, G., et al. (2018) C-Reactive Protein in Atherothrombosis and Angiogenesis. Frontiers in Immunology, 9, Article No. 430. [Google Scholar] [CrossRef] [PubMed]
[10] Li, Y.W., Zhong, X.M., Cheng, G.C., et al. (2017) Hs-CRP and All-Cause, Cardiovascular, and Cancermortality Risk: A Meta-Analysis. Atherosclerosis, 259, 75-82. [Google Scholar] [CrossRef] [PubMed]
[11] Held, C., White, H.D., Stewart, R.A.H., et al. (2017) Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Journal of the American Heart Association, 6, e005077. [Google Scholar] [CrossRef] 
[12] Green, D., Foiles, N., Chan, C.L., et al. (2010) An Association between Clotting Factor VII and Carotid Intima-Media Thickness: The CARDIA Study. Stroke, 41, 1417-1422. [Google Scholar] [CrossRef] 
[13] Fotis, L., Agrogiannis, G., Vlachos Ioannis, S., et al. (2012) Intercellular Adhesion Molecule (ICAM)-1 and Vascular Cell Adhesion Molecule (VCAM)-1 at the Early Stages of Atherosclerosis in a Rat Model. In Vivo, 26, 243-250.
[14] Konstantino, Y., Nguyen, T.T., Wolk, R., et al. (2009) Potential Implications of Matrix Metalloproteinase-9 in Assessment and Treatment of Coronary Artery Disease. Biomarkers, 14, 118-129. [Google Scholar] [CrossRef] [PubMed]
[15] Sriramula, S., Cardinale, J.P., Lazartigues, E., et al. (2011) ACE2 Overexpression in the Paraventricular Nucleus Attenuates Angiotensin II-Induced Hypertension. Cardiovascular Research, 92, 401-408. [Google Scholar] [CrossRef] [PubMed]
[16] Jin, H.Y., Song, B., Oudit, G.Y., et al. (2012) ACE2 Deficiency Enhances Angiotensin II-Mediated Aortic Profilin-1 Expression, Inflammation and Peroxynitrite Production. PLoS ONE, 7, e38502. [Google Scholar] [CrossRef] [PubMed]
[17] Sahara, M., Ikutomi, M., Morita, T., et al. (2014) Deletion of Angiotensin-Converting Enzyme 2 Promotes the Development of Atherosclerosis and Arterial Neointima Formation. Cardiovascular Research, 101, 236-246. [Google Scholar] [CrossRef] [PubMed]
[18] Mehta, P.K. and Griendling, K.K. (2006) Angiotensin II Cell Signaling: Physiological and Pathological Effects in the Cardiovascular System. American Journal of Physiology. Cell Physiology, 292, C82-C97. [Google Scholar] [CrossRef] [PubMed]
[19] Song, B., Jin, H.Y., Yu, X., et al. (2013) Angiotensin-Converting Enzyme 2 Attenuates Oxidative Stress and VSMC Proliferation via the JAK2/STAT3/SOCS3 and Profilin-1/MAPK Signaling Pathways. Regulatory Peptides, 185, 44-51. [Google Scholar] [CrossRef] [PubMed]
[20] Song, J.T., Qu, H.Y., Hu, B., et al. (2020) Physiological Cyclic Stretch Up-Regulates Angiotensin-Converting Enzyme 2 Expression to Reduce Proliferation and Migration of Vascular Smooth Muscle Cells. Bioscience Reports, 40, BSR20192012. [Google Scholar] [CrossRef] 
[21] Schroeder, A.P. and Falk, E. (1995) Vulnerable and Dangerous Coronary Plaques. Atherosclerosis, 118, S141-S149. [Google Scholar] [CrossRef] [PubMed]
[22] Fraga-Silva, R.A., Savergnini, S.Q., Montecucco, F., et al. (2014) Treatment with Angiotensin-(1-7) Reduces Inflammation in Carotid Atherosclerotic Plaques. Thrombosis and Haemostasis, 111, 736-747. [Google Scholar] [CrossRef] 
[23] Lovren, F., Pan, Y., Quan, A., et al. (2008) Angiotensin Converting Enzyme-2 Confers Endothelial Protection and Attenuates Atherosclerosis. American Journal of Physiology: Heart and Circulatory Physiology, 295, H1377-H1384. [Google Scholar] [CrossRef] [PubMed]
[24] Zhang, C., Zhao, Y.X., Zhang, Y.H., et al. (2010) Angiotensin-Converting Enzyme 2 Attenuates Atherosclerotic Lesions by Targeting Vascular Cells. Proceedings of the National Academy of Sciences of the United States of America, 107, 15886-15891. [Google Scholar] [CrossRef] [PubMed]
[25] Lin, Y.J., Zeng, H.S., Gao, L., et al. (2017) Hydrogen Sulfide Attenuates Atherosclerosis in a Partially Ligated Carotid Artery Mouse Model via Regulating Angiotensin Converting Enzyme 2 Expression. Frontiers in Physiology, 8, Article No. 782. [Google Scholar] [CrossRef] [PubMed]
[26] Yang, J.M., Yang, X.Y., Meng, X., et al. (2015) Endogenous Activated Angiotensin-(1-7) Plays a Protective Effect against Atherosclerotic Plaques Unstability in High Fat Diet Fed ApoE Knockout Mice. International Journal of Cardiology, 184, 645-652. [Google Scholar] [CrossRef] [PubMed]
[27] Zhang, Y.H., Zhang, Y.H., Dong, X.F., et al. (2015) ACE2 and Ang-(1-7) Protect Endothelial Cell Function and Prevent Early Atherosclerosis by Inhibiting Inflammatory Response. Inflammation Research, 64, 253-260. [Google Scholar] [CrossRef] [PubMed]

为你推荐